Viewing Study NCT06101134

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:37 AM
Ignite Modification Date: 2026-02-05 @ 8:27 PM
Study NCT ID: NCT06101134
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-04-14
First Post: 2023-10-20
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Sponsor: Bristol-Myers Squibb
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Melanoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Patient preference View
None Nivolumab Relatlimab IV View
None Nivolumab Relatimab SC View
None Melanoma View
None rHuPH20 View
None FDC IV View
None FDC SC View
None Adjuvant View
None Metastatic View
None Switch View
None Nivolumab View
None Relatlimab View